Icosavax, a Seattle-based vaccine design company born from innovative research conducted here at the Institute for Protein Design, will be acquired by AstraZeneca in a deal worth up to $1.1 billion. MORE
Icosavax, a Seattle-based vaccine design company born from innovative research conducted here at the Institute for Protein Design, will be acquired by AstraZeneca in a deal worth up to $1.1 billion. MORE